Clinical Research Directory

Inclusion Criteria: Favorable risk and low-tier intermediate-risk prostate cancer with estimated life expectancy of at least 10 years. * Clinical stage T1c-T2b, PSA \< 20, Gleason \< 8 * ECOG 0-1 * Low tier intermediate-risk prostate cancer is defined by a single NCCN intermediate risk factor * Extensive favorable-risk disease is defined as: * clinical stage T1c-T2a * PSA \< 10 * Gleason 6 * ≥ 50% of biopsy cores containing cancer * PSA density \> 0.2 ng/cc * Selected intermediate risk patients not defined above * \- T1c/T2a * \- PSA \< 10 * -Gleason 4+3 * PSA \> 10 and Gleason 3+4 * PSA 10-15 ng/ml and Gleason 4+3 * -\< 33% of cores involved * -Max tumor length in any core 10 mm * No androgen deprivation therapy (ADT) * Prostate volume by TRUS ≤ 60 cc. * Not eligible for, or accepting of, active surveillance according to NCCN guidelines. * Signed study specific informed consent. Exclusion Criteria: * Prior radical surgery for carcinoma of the prostate, * Prior pelvic radiation * Prior chemotherapy for prostate cancer, * Prior TURP or cryosurgery of the prostate * Claustrophobic or unable to undergo MRI